Novo Nordisk Maps Out a Future Beyond Weight Loss, but Investors Are Counting the Days to 2027
Novo Nordisk unveils longevity and aesthetics strategy at ADA, but stock languishes as CagriSema approval not expected until…
Browsing Tag